DKK3

DUBLIN, Dec. 13, 2023 /PRNewswire/ -- The "MTG201 + nivolumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about MTG201 + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets. A detailed picture of the MTG201 + nivolumab for MPM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the MTG201 + nivolumab for MPM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MTG201 + nivolumab market forecast analysis for MPM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in MPM. Drug Summary MTG201 is novel investigational gene therapy with unique dual mechanisms of action capable of addressing a range of cancers. The drug candidate leverages the company's proprietary adenoviral vector technology platform to deliver the reduced expression in immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene is markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. At the same time, increased expression of the REIC/Dkk3 gene in normal cell components in tumor tissue promotes antitumor immunity by activating dendritic cells and natural killer (NK) cells while suppressing immune-suppressive regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSC). Based on these novel dual mechanisms, MTG201 is believed to be well-positioned to work synergistically with checkpoint inhibitors such as nivolumab. The Phase II trial (NCT04013334), conducted at the Baylor College of Medicine in Houston, Texas, is an open-label, single-arm study designed to assess the efficacy, safety, and tolerability of intratumoral administration of MTG201 in combination with nivolumab. The trial enrolled up to twelve patients with malignant mesothelioma who have failed front-line systemic platin-based chemotherapy. The study's primary objective is to assess the efficacy of the treatment combination, with the primary endpoint being objective response rate (ORR). MTG201 + nivolumab Analytical Perspective In-depth MTG201 + nivolumab Market Assessment This report provides a detailed market assessment of MTG201 + nivolumab for malignant pleural mesothelioma (MPM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032. MTG201 + nivolumab Clinical Assessment The report provides the clinical trials information of MTG201 + nivolumab for MPM covering trial interventions, trial conditions, trial status, start and completion dates. Report Highlights In the coming years, the market scenario for malignant pleural mesothelioma (MPM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market. The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MTG201 + nivolumab dominance. Other emerging products for MPM are expected to give tough market competition to MTG201 + nivolumab and launch of late-stage emerging therapies in the near future will significantly impact the market. A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MTG201 + nivolumab in MPM. This in-depth analysis of the forecasted sales data of MTG201 + nivolumab from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MTG201 + nivolumab in MPM. Key Topics Covered: 1. Report Introduction 2. MTG201 + nivolumab Overview in MPM 2.1. Product Detail 2.2. Clinical Development 2.2.1. Clinical studies 2.2.2. Clinical trials information 2.2.3. Safety and efficacy 2.3. Other Developmental Activities 2.4. Product Profile 3. Competitive Landscape (Marketed Therapies) 4. Competitive Landscape (Late-stage Emerging Therapies) 5. MTG201 + nivolumab Market Assessment 5.1. Market Outlook of MTG201 + nivolumab in MPM 5.2. 7MM Analysis 5.2.1. Market Size of MTG201 + nivolumab in the 7MM for MPM 5.3. Country-wise Market Analysis 5.3.1. Market Size of MTG201 + nivolumab in the United States for MPM 5.3.2. Market Size of MTG201 + nivolumab in Germany for MPM 5.3.3. Market Size of MTG201 + nivolumab in France for MPM 5.3.4. Market Size of MTG201 + nivolumab in Italy for MPM 5.3.5. Market Size of MTG201 + nivolumab in Spain for MPM 5.3.6. Market Size of MTG201 + nivolumab in the United Kingdom for MPM 5.3.7. Market Size of MTG201 + nivolumab in Japan for MPM 6. SWOT Analysis 7. Analysts' Views For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo - SOURCE Research and Markets

Stablix Therapeutics launched with a $63 million Series A financing round that will be used to develop the company’s and advance a portfolio of protein stabilizers towards the clinic. New York-based Stablix’s TPS platform, dubbed RESTORED, “generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity,” according to the company announcement. Stablix will initially aim the platform to develop programs that treat rare diseases, cancer, and immunological disorders. With the RESTORED platform, Stablix said it’s possible to inhibit the ubiquitin-proteasome system in a target-selective manner to treat some of these diseases. “Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner,” Carlo Rizzuto, a partner at Versant and acting Chief Executive Officer of Stablix said in a statement. “We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.” The company pointed to cystic fibrosis as a disease that could benefit from its approach. Stablix said mutations in the CFTR gene produce a functional protein that is subject to excessive ubiquitination. This can lead to rapid degradation through the proteasome. Excess ubiquitination is also a hallmark of some cancers, where E3 ubiquitin ligases are “frequently upregulated or amplified.” This drives the degradation of tumor suppressor proteins, the company added. The Series A financing round was led by Versant Ventures, the founding investor of Stablix. NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities also contributed. Stablix wasn’t the only company to announced funds from a Series A financing round this morning. Texas-based Stellanova Therapeutics, a resident company at JLABS @ TMC, closed a $15.5 million Series A financing round. Funds will be used to support the development of antibody drugs and a discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, which can render resistant cancers treatable. Stellanova aims to advance its lead antibody asset into the clinic. Stellanova is focused on targeting pro-tumorigenic effects enabled by the activity of carcinoma-associated fibroblasts (known as CAFs) in the tumor microenvironment. These CAFs play significant roles in promoting cancer growth and metastasis. They spur angiogenesis, suppress anti-tumor immunity, and foster chemoresistance. Stellanova’s lead antibody candidate is designed to neutralize DKK3, a factor secreted by CAFs that acts on neighboring cancer cells and immune cells to promote tumor progression and therapy resistance. Rosa Hwang, co-founder of Stellanova, said the company’s lead antibody shows robust anti-tumor activity, alone or together with immune therapy, in highly refractory preclinical models of the pancreas and triple negative breast cancer. The Series A financing round was led by Sporos Bioventures, LLC. Belgium-based Amyl Therapeutics raised €18.3 million ($22.3 million) in Series A funding. The company will use funds from the round to advance the discovery and development of preclinical therapeutic candidates that can target multiple misfolded proteins implicated in both progressive peripheral and rare neurodegenerative diseases. The company’s amyloid fibrils specific technology platform dubbed ClariTY was developed for the treatment of all forms of Amyloidosis, which can be seen in diseases such as Alzheimer’s and Parkinson’s. Therapeutic assets based on the ClariTY platform are designed to prevent the further accumulation of these amyloid aggregates and clear existing aggregates from the peripheral organs and the brain. Also, they are designed to block further “cell-to-cell spread of misfolded proteins.” The company believes these therapies may offer a breakthrough approach to treat protein misfolding diseases. The financing round was composed of an €8.6 million equity investment led by Belgium-based Noshaq, with participation from Merieux Participations, Sambrinvest, and other private investors. Additionally, a non-dilutive funding of €9.7 million was made by the DG06, a Belgium-based policy-design and implementing body.

The three companies will aim to develop their different programs such as Stablix TPS platform, Stellanova’s focused on targeting pro-tumorigenic effects, and Amyl’s development of preclinical therapeutic candidates. Stablix Therapeutics launched with a $63 million Series A financing round that will be used to develop the company’s and advance a portfolio of protein stabilizers towards the clinic. New York-based Stablix’s TPS platform, dubbed RESTORED, “generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity,” according to the company announcement. Stablix will initially aim the platform to develop programs that treat rare diseases, cancer, and immunological disorders. With the RESTORED platform, Stablix said it’s possible to inhibit the ubiquitin-proteasome system in a target-selective manner to treat some of these diseases. “Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner,” Carlo Rizzuto, a partner at Versant and acting Chief Executive Officer of Stablix said in a statement. “We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.” The company pointed to cystic fibrosis as a disease that could benefit from its approach. Stablix said mutations in the CFTR gene produce a functional protein that is subject to excessive ubiquitination. This can lead to rapid degradation through the proteasome. Excess ubiquitination is also a hallmark of some cancers, where E3 ubiquitin ligases are “frequently upregulated or amplified.” This drives the degradation of tumor suppressor proteins, the company added. The Series A financing round was led by Versant Ventures , the founding investor of Stablix. NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities also contributed. Stablix wasn’t the only company to announced funds from a Series A financing round this morning. Texas-based Stellanova Therapeutics, a resident company at JLABS @ TMC, closed a $15.5 million Series A financing round . Funds will be used to support the development of antibody drugs and a discovery platform targeting pro-tumorigenic factors produced by fibroblasts in the tumor microenvironment, which can render resistant cancers treatable. Stellanova aims to advance its lead antibody asset into the clinic. Stellanova is focused on targeting pro-tumorigenic effects enabled by the activity of carcinoma-associated fibroblasts (known as CAFs) in the tumor microenvironment. These CAFs play significant roles in promoting cancer growth and metastasis. They spur angiogenesis, suppress anti-tumor immunity, and foster chemoresistance. Stellanova’s lead antibody candidate is designed to neutralize DKK3, a factor secreted by CAFs that acts on neighboring cancer cells and immune cells to promote tumor progression and therapy resistance. Rosa Hwang, co-founder of Stellanova, said the company’s lead antibody shows robust anti-tumor activity, alone or together with immune therapy, in highly refractory preclinical models of the pancreas and triple negative breast cancer. The Series A financing round was led by Sporos Bioventures, LLC. Belgium-based Amyl Therapeutics raised €18.3 million ($22.3 million) in Series A funding . The company will use funds from the round to advance the discovery and development of preclinical therapeutic candidates that can target multiple misfolded proteins implicated in both progressive peripheral and rare neurodegenerative diseases. The company’s amyloid fibrils specific technology platform dubbed ClariTY was developed for the treatment of all forms of Amyloidosis, which can be seen in diseases such as Alzheimer’s and Parkinson’s. Therapeutic assets based on the ClariTY platform are designed to prevent the further accumulation of these amyloid aggregates and clear existing aggregates from the peripheral organs and the brain. Also, they are designed to block further “cell-to-cell spread of misfolded proteins.” The company believes these therapies may offer a breakthrough approach to treat protein misfolding diseases. The financing round was composed of an €8.6 million equity investment led by Belgium-based Noshaq, with participation from Merieux Participations, Sambrinvest, and other private investors. Additionally, a non-dilutive funding of €9.7 million was made by the DG06, a Belgium-based policy-design and implementing body.